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NEW THERAPEUTIC STRATEGIES FOR ALZHEIMER’S DISEASE:
NEW TREATMENTS AGAINST BETA-AMYLOID AND TAU-PROTEIN
OBJECTIVES
• To expound how some proteins are involved in the development of the disease and which mechanism is followed.
• To show new drugs that have been tested in clinical trials, how they act and the results obtained in the studies.
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ß-Amyloid
ß-Amyloid peptide is a product of cleavage of a precursor protein (APP). First, it can be
cleaved by two secretases: α- and ß-secretase. Depending on the secretase involved in
the cleavage the process will be Non-Amyloidogenic or Amyloidogenic.
Later, Amyloid precursor protein is cleaved by a γ-secretase. Amyloidogenic products can
be misfolded and form harmful aggregates, leading to cell death and inflammation [2].
Tau-protein
Tau-protein promotes tubulin polymerization. It is a microtubule-associated Tau-
protein (MAPT) mainly found in axons and stimulates the assembling of microtubules.
In a healthy brain, 2 or 3 residues on tau are phosphorylated. In contrast, in
Alzheimer’s disease and other tauopathies, there is a hyperphosphorylation in different
residues.
Moreover, hyperphosphorylation stimulates fibrillization and aggregation into
neurofibrillary tangles (NFT) [2].
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Alzheimer’s disease (AD) is the most common cause of dementia (more than 50% of all the cases), affecting up to 8 % of the elderly population worldwide. It is considered to be
the most frequent neurodegenerative disease. It has been demonstrated that the disease initiates with the early accumulation of ß-Amyloid at the preclinical stage in the neocortex
and subsequently Tau-protein accumulation, inflammatory process and cognitive disturbances appear [1].
Figure 1. Aggregation and accumulation of ß-Amyloid and Tau-protein in the brain. On the left, it can be observed how ß- and γ-
secretases cleave APP, leading to ß-Amyloid formation. On the right, there is a scheme of neurofibrillary tangles formation.
Novel therapeutic strategies
Against β-Amyloid Against γ- and β-secretases Against Tau-protein
Immunotherapy. It can be directed against APP,
monomeric Aß, soluble oligomers, insoluble fibrils and
carrier proteins.
 Active immunization. Prolonged antibody response
using a small number of vaccinations. Example:
ACCD-001 that contained a six amino acid
sequence Aß1-6 with a surface-active saponin-
adjuvant QS-21. Phase II trials showed adverse
effects.
 Passive immunization. Antibodies delivery from the
patient’s own immune system, humanized murine
monoclonal antibodies or human donors of
polyclonal antibodies. Example: Solanezeumab, a
monoclonal antibody that binds specifically to the
mid-domain of Aß (Aß16-24). Positive therapeutic
effects at an early stage were obtained [3].
 γ-secretase inhibitors (GSIs). GSIs are capable of
inhibiting the cleavage of ß-Amyloid protein (Beta-
Amyloid production inhibitors). Example: ELND006 that
was removed at an early stage because induced
noticeable side effects [4].
 γ-secretase modulators. Regulate the functionality of γ-
secretase. Example: Avagacestat interacts with shorter
forms of Beta-Amyloid and alters the proteolytic activity
of the protease without affecting Notch protein
transformation [1].
 ß–secretase inhibitors. Small molecule inhibitors.
Interfere with the amyloid formation pathway. Example:
MK-8931 has shown dosage-dependent reduction in the
level of Beta-Amyloid in the cerebrospinal fluid in more
than 80% of patients [1].
 Immunotherapy. Intends to prevent formation of
neurofibrillary tangles. It has been found that
antibodies against Tau-protein can bound to
pathological Tau-proteins. Some vaccines have been
developed. Example: ACI-35, an example for active
immunization tested in mild-to-moderate AD
patients. Otherwise, passive immunization appears to
show less side effects [5].
 Hindering phosphorylation of Tau-Protein to
prevent aggregation. It appears to be a bright
strategy for the treatment of AD, even in the
symptomatic phase of the disease. Example: LMTX
showed prevention of Tau interactions, an increment
in clearance of Tau from the brain and anti-β-
Amyloid aggregation activity [1,5].
CONCLUSIONS
• Although there have been several clinical trials, most phase II trials with positive results do not succeed in phase III and show either adverse effects or lack of therapeutic efficacy.
• Even though there are still studies focused on Aß protein, novel therapies are now directed against other proteins involved in the progression of the disease, for instance, Tau
protein or secretase inhibitors. These strategies seem to be promising and may be the answer to cure Alzheimer’s disease.
• In conclusion, better knowledge of the disease and the outcome of useful and potent biomarkers will lead to the development of an effective drug.
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